1. Recurrence-free survival
cor
P value (K-M)
P-value (Cx)
RNF44 -1
0.236
0.385
HOXB8
0.0316
0.0447
TBX1
0.036
0.18
BAD 1
0.0984
0.142
ADRBK1
0.0847
0.286
OSR1
0.0117
0.34
MPDU1
0.0321
0.253
cor
P value (K-M)
P-value (Cx)
RNF44 -1
0.0435
0.0746
HOXB8
0.01
0.0197
TBX1
0.0946
0.289
BAD 1
0.0222
0.128
ADRBK1
0.112
0.274
OSR1
0.0533
0.377
MPDU1
0.0357
0.328
Overall survival
Recurrence-free survival
cor 1: survival improved with higher expression
cor -1: survival improved with lower expression
Supplementary Table 1
The prognostic impact of nine potential target genes was analyzed using the data from 242 HCC cases of a previous report (Roessler S. et al. Gastroenterology 2012;142:957–966).

2. miR-718 high (n=11) miR-718 low (n=48) 1 2 3 4 5 6 7
0.2
0.4
0.6
0.8
1.0 1 2 3 4 5 6 7
miR-718 low (n=48)
miR-718 high (n=11)
Years after transplantation
Recurrence-free survival (%)
Supplementary Figure 1
Recurrence-free survival curves of patients with high (n=11) and low miR-718 expression (n=48) in exosomes from serum. No patients with high miR-718 expression had recurrent disease, but six of 48 patients with low miR-718 expression had recurrent hepatocellular carcinoma after liver transplantation (p=0.13, log-rank test).

3. miR-718 high and/or <3cm (n=44)
0.0
0.2
0.4
0.6
0.8
1.0
miR-718 high and/or <3cm (n=44)
miR-718 low and ≥3cm (n=15)
Recurrece-free survival (%) 1 3 5 7 9
Years after transplantation
Supplementary Figure 2
Recurrence-free survival curves of patients with miR-718 high and tumor diameter <3cm (n=) and miR-718 low and tumor diameter ≥3cm (n=). (p=0.002, log-rank test).

4. Recurrence-free survivalb
Low HOXB8
Low HOXB8
High HOXB8
High HOXB8
p=0.0316
p=0.01
Overall survival
Recurrence-free survival
Supplementary Figure 3
The overall (a) and recurrence-free (b) survival curves of 242 HCC cases with high and low HOXB8 expression, according to the data of a previous report (Roessler S. et al. Gastroenterology 2012;142:957–966).